Skip to main content

Genedata accelerating drug development

| News

Genedata accelerating drug development


Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Genedata has developed a platform for managing data from biopharmaceutical research. This platform also allows data to be brought together from different sources and then processed. The announced collaboration with international pharmaceutical and laboratory equipment supplier Thermo Fisher will now enable the direct integration of Thermo Fisher’s robotics and automation platforms with the Genedata Biopharma Platform, as was reported in a Genedata press release.

The two companies will consequently be able to offer scientists a centralized platform that delivers automation systems for sample handling, lab operations and testing and enables them to digitally trace all results for every sample of imported raw instrument data. This will accelerate the discovery and development of next-generation biotherapeutics, the Basel IT company says. Integrating the two platforms gives researchers the power to make data-based decisions and uncover insights not possible before, explained Hansjoerg Hass, Senior Director Lab Automation at Thermo Fisher.

The integration includes both laboratory instruments and software from Thermo Fisher. Both companies are implementing interfaces for the seamless integration of all areas of the two platforms. Genedata has extensive experience in projects of this kind, with the Basel company’s IT solutions having been used by other major players to automate complex laboratory workflows with lab equipment, as Othmar Pfannes, CEO of Genedata, outlines.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.